---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011402"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:10:36.450633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evofem posts $18.2M Phexxi net sales in 2023; operating loss improves 79% YoY; Aditxt acquisition pending

## Summary
- Net product sales $18.2M, up from $16.8M in 2022; Q4 sales $4.8M vs $0.2M.
- Total operating expenses reduced 64% to $36.1M from $101.0M; selling and marketing down 73%.
- Loss from operations improved to $17.8M from $84.1M (79% improvement).
- Entered definitive agreement to be acquired by Aditxt (ADTX); expected closing H2 2024.
- Cash: $0.6M restricted at Dec 2023; compared to $2.8M unrestricted at Dec 2022.

## SEC filing metadata
- accession: 0001493152-24-011402
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011402
- JSON: https://secwatch.observer/filing/0001493152-24-011402.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011402.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported year ended December 31, 2023 results: revenue $18.2 million.
  - Period: year ended December 31, 2023
  - Revenue: $18.2 million
  - Result: reported results
  source text: For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm
- Earnings Releases
  Evofem Biosciences, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million.
  - Period: three months ended December 31, 2023
  - Revenue: $4.8 million
  - Result: reported results
  source text: For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.